Carcinoid Syndrome & VIPomas

Sandostatin LAR® Depot and Carcinoid Syndrome

Sandostatin LAR® Depot (octreotide acetate for injectable suspension) is a mainstay of therapy for carcinoid syndrome, which provides targeted treatment for carcinoid syndrome.

• Reduction of Bioactive Secretions
• Control of 5-HIAA Levels
• Reduction in Diarrhea Frequency and Flushing Episodes

Reduction of Bioactive Secretions

Sandostatin LAR® Depot* reduces bioactive secretions to provide important biochemical control of carcinoid syndrome (1)

• Highly active secretions such as serotonin, neurotensin, vasoactive intestinal peptide, and pancreatic polypeptide are distributed throughout a patient's body - causing debilitating symptoms (2, 3)
• Effective disease management can be reached with a therapeutic agent that suppresses bioactive secretions and controls debilitating symptoms
• Sandostatin LAR® Depot works at the site of carcinoid tumors, binding to sst-2 and sst-5 receptors, to reduce hypersecretions (4, 5, 6)

Patient Case Study: Sandostatin LAR® Depot Reduces Peptide Concentrations (3)

Control of 5-HIAA Levels

Suppressing 5-HIAA Levels, a metabolite of serotonin, is key for assessing and managing a patient with carcinoid syndrome (2, 7). A positive correlation between tumor mass and urinary 5-HIAA levels allows for use of 5-HIAA to estimate the extent of carcinoid disease (2, 7).

Sandostatin LAR® Depot Provides Up to 50% Suppression of 5-HIAA Levels (8, 9)

Reduction in Diarrhea Frequency and Flushing Episodes

By working at the site of carcinoid tumors, Sandostatin LAR® Depot reduces bioactive secretions and controls diarrhea frequency and flushing episodes (1):

• Bioactive tumor secretions such as serotonin, histamine, and vasoactive intestinal polypeptide (VIP) are implicated in the chronic secretory diarrhea unique to carcinoid syndrome (1, 10)
• Uncontrolled diarrhea due to carcinoid syndrome leaves patients at risk for serious comorbidities such as opportunistic intestinal infections and dehydration (4, 8, 10)
• Diarrhea is the primary impetus for patients to seek medical help, making effective long-term treatment necessary
• Sandostatin LAR® Depot reduces flushing episodes from 4.5 episodes/day to 0.7 episodes/day (8, 9)

The Mainstay of Medical Therapy for Carcinoid Syndrome

Sandostatin LAR® Depot:

• Reduced 5-HIAA levels by up to 50% (8, 9)
• Reduced diarrhea frequency by 42% (8, 9)*
• Reduced flushing frequency by 84% (8, 9)*
• Provides smooth, consistent drug levels for the entire once-monthly treatment period at all doses after steady state is attained (11)
• Offers a well-established safety profile (8)
• Can provide additional control to treat symptom flare-ups*

*Patients with carcinoid tumors often experience symptom flareups while being maintained on immediate release Sandostatin® Injection or Sandostatin LAR® Depot. They may be given immediate release Sandostatin® Injection for a few days (at the dosage they were receiving prior to switch to Sandostatin LAR® Depot) until symptoms are again controlled.